Trial Outcomes & Findings for Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) (NCT NCT03354143)
NCT ID: NCT03354143
Last Updated: 2025-07-02
Results Overview
Changes (12 month timepoint minus baseline) in intracranial pulsatility will be measured with CINE phase-contrast MRI. We will use the velocity-encoded CINE PC MRI to measure intracranial pulsatility. Pulsatility measured in mm per cardiac cycle
COMPLETED
PHASE2
85 participants
Baseline and 12-months
2025-07-02
Participant Flow
85 participants enrolled include 40 (Control group subjects-no intervention) and 45 participants (undergo intervention). These 45 subjects are randomized to either Standard care or Intensive care interventions that is summarized in the table below. Control group was not randomized and they did not receive an experimental intervention but received SOC.
Participant milestones
| Measure |
Standard Care
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Overall Study
STARTED
|
19
|
26
|
40
|
|
Overall Study
COMPLETED
|
17
|
22
|
40
|
|
Overall Study
NOT COMPLETED
|
2
|
4
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
Baseline characteristics by cohort
| Measure |
Standard Care
n=19 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=26 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
n=40 Participants
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
Total
n=85 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
5 Participants
n=39 Participants
|
18 Participants
n=41 Participants
|
19 Participants
n=35 Participants
|
42 Participants
n=31 Participants
|
|
Age, Categorical
>=65 years
|
14 Participants
n=39 Participants
|
8 Participants
n=41 Participants
|
21 Participants
n=35 Participants
|
43 Participants
n=31 Participants
|
|
Age, Continuous
|
68.9 years
STANDARD_DEVIATION 5.8 • n=39 Participants
|
62.8 years
STANDARD_DEVIATION 6.4 • n=41 Participants
|
60.3 years
STANDARD_DEVIATION 6.6 • n=35 Participants
|
65.5 years
STANDARD_DEVIATION 6.7 • n=31 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=39 Participants
|
16 Participants
n=41 Participants
|
22 Participants
n=35 Participants
|
47 Participants
n=31 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=39 Participants
|
10 Participants
n=41 Participants
|
18 Participants
n=35 Participants
|
38 Participants
n=31 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=39 Participants
|
2 Participants
n=41 Participants
|
3 Participants
n=35 Participants
|
6 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Black or African American
|
6 Participants
n=39 Participants
|
3 Participants
n=41 Participants
|
2 Participants
n=35 Participants
|
11 Participants
n=31 Participants
|
|
Race (NIH/OMB)
White
|
12 Participants
n=39 Participants
|
21 Participants
n=41 Participants
|
35 Participants
n=35 Participants
|
68 Participants
n=31 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
|
Region of Enrollment
United States
|
19 participants
n=39 Participants
|
26 participants
n=41 Participants
|
40 participants
n=35 Participants
|
45 participants
n=31 Participants
|
PRIMARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
Changes (12 month timepoint minus baseline) in intracranial pulsatility will be measured with CINE phase-contrast MRI. We will use the velocity-encoded CINE PC MRI to measure intracranial pulsatility. Pulsatility measured in mm per cardiac cycle
Outcome measures
| Measure |
Standard Care
n=19 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=26 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Changes in Gray Matter Intracranial Pulsatility
|
-0.09 mm/cardiac cycle
Standard Deviation 0.04
|
0.02 mm/cardiac cycle
Standard Deviation 0.03
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
changes in overall average 24 hr ambulatory systolic blood pressure will be assessed SpaceLabs monitor
Outcome measures
| Measure |
Standard Care
n=19 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=26 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Changes in Overall Average 24 Hour Systolic Blood Pressure
|
17.9 mmHg
Standard Deviation 3.3
|
23.6 mmHg
Standard Deviation 2.8
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
changes in overall average 24 hr ambulatory diastolic blood pressure will be assessed SpaceLabs monitor
Outcome measures
| Measure |
Standard Care
n=19 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=26 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Changes in Overall Average 24hr Diastolic Blood Pressure
|
10.9 mmHg
Standard Deviation 1.5
|
12 mmHg
Standard Deviation 1.2
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
Outcome measures
| Measure |
Standard Care
n=15 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=22 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Regional Cortical Thickness Via Magnetic Resonance Imaging (MRI)
12 month
|
2.3 mm
Standard Deviation 0.09
|
2.3 mm
Standard Deviation 0.09
|
—
|
|
Regional Cortical Thickness Via Magnetic Resonance Imaging (MRI)
Baseline
|
2.3 mm
Standard Deviation 0.09
|
2.4 mm
Standard Deviation 0.08
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
White matter hyperintensities (WMH) on brain T2 fluid-attenuated inversion recovery (FLAIR) magnetic resonance images (MRI) are commonly observed in older adults over 65 years old, and more extensive in those with vascular or Alzheimer's disease type of dementia. Qualitative and quantitative WMH characterization has been used as a biomarker to assist cerebral small vessel disease diagnosis and to assess treatment effects. In this report, the size of the WMH has been assessed with the PGS software, the top performer of the deep-learning algorithms from the 2017 MICCAI WMH segmentation challenge. The unit of the WMH total size presented in this report is in mL.
Outcome measures
| Measure |
Standard Care
n=15 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=22 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Brain White Matter Hyperintensity (WMH) Via Magnetic Resonance Imaging (MRI)
Baseline
|
7.9 ml
Standard Deviation 12.9
|
2.8 ml
Standard Deviation 3.2
|
—
|
|
Brain White Matter Hyperintensity (WMH) Via Magnetic Resonance Imaging (MRI)
12 Month
|
7.5 ml
Standard Deviation 13.0
|
2.6 ml
Standard Deviation 2.9
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
Fractional Anisotropy (FA) values are a measure of how directed diffusion is in a tissue, typically ranging from 0 to 1. A value of 0 indicates isotropic diffusion (diffusion is the same in all directions), while a value of 1 indicates highly anisotropic diffusion (diffusion is restricted to a single direction). FA is often used in diffusion tensor imaging (DTI) and is thought to reflect fiber density, axonal diameter, and myelination in white matter.
Outcome measures
| Measure |
Standard Care
n=15 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=22 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Brain White Matter Microstructural Integrity Via Magnetic Resonance Imaging (MRI)
Baseline
|
0.4 Mean fractional anisotropy from DTI
Standard Deviation 0.02
|
0.4 Mean fractional anisotropy from DTI
Standard Deviation 0.02
|
—
|
|
Brain White Matter Microstructural Integrity Via Magnetic Resonance Imaging (MRI)
12 Month
|
0.4 Mean fractional anisotropy from DTI
Standard Deviation 0.01
|
0.4 Mean fractional anisotropy from DTI
Standard Deviation 0.01
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
The brain's functional connectivity, particularly within the Default Mode Network (DMN), can be assessed using functional magnetic resonance imaging (fMRI) through the correlations between the activity of the brain regions within a network. In this report, the DMN regions were identified with a seed-based approach from another clinical trial with 420 subjects of a similar population. By identifying regions of interest (ROIs) within the DMN, researchers can analyze how these regions connect and interact with each other, revealing information about brain activity and potentially aiding in the diagnosis and understanding of various neurological and psychiatric conditions. Here, the functional connectivity of the DMN brain regions is reported in the unit of Pearson correlation R, with a range of 0 to 1 in this application. A high R value indicates a high level of connectivity.
Outcome measures
| Measure |
Standard Care
n=14 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=21 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
Brain Neural Network Functional Connectivity Via Magnetic Resonance Imaging (MRI)
Baseline
|
0.39 Pearson correlation R (r value)
Standard Deviation 0.083
|
0.42 Pearson correlation R (r value)
Standard Deviation 0.14
|
—
|
|
Brain Neural Network Functional Connectivity Via Magnetic Resonance Imaging (MRI)
12 Month
|
0.39 Pearson correlation R (r value)
Standard Deviation 0.079
|
0.4 Pearson correlation R (r value)
Standard Deviation 0.08
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function).A score of 60 is one standard deviation above the average population
Outcome measures
| Measure |
Standard Care
n=17 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=24 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
NIH PROMIS Patient-reported Outcome Measures of Physical Health
Baseline
|
52.1 T score
Standard Deviation 6.4
|
51.0 T score
Standard Deviation 6.3
|
—
|
|
NIH PROMIS Patient-reported Outcome Measures of Physical Health
12 Month
|
50.9 T score
Standard Deviation 7.5
|
51.8 T score
Standard Deviation 7.4
|
—
|
SECONDARY outcome
Timeframe: Baseline and 12-monthsPopulation: Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). A score of 60 is one standard deviation above the average population
Outcome measures
| Measure |
Standard Care
n=17 Participants
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=24 Participants
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
Control Group
Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC).
|
|---|---|---|---|
|
NIH PROMIS Patient-reported Outcome Measures of Mental Health
Baseline
|
56.0 T sore
Standard Deviation 7.5
|
52.1 T sore
Standard Deviation 7.4
|
—
|
|
NIH PROMIS Patient-reported Outcome Measures of Mental Health
12 Month
|
54.9 T sore
Standard Deviation 8.4
|
54.0 T sore
Standard Deviation 6.3
|
—
|
Adverse Events
Standard Care
Intensive Treatment
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Standard Care
n=19 participants at risk
Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
|
Intensive Treatment
n=26 participants at risk
Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
|
|---|---|---|
|
General disorders
Abnormal laboratory measure
|
0.00%
0/19 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
3.8%
1/26 • Number of events 1 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
|
General disorders
Orthostatic hypotension
|
10.5%
2/19 • Number of events 2 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
3.8%
1/26 • Number of events 1 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
|
General disorders
Dizziness
|
5.3%
1/19 • Number of events 1 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
15.4%
4/26 • Number of events 4 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
26.3%
5/19 • Number of events 5 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
3.8%
1/26 • Number of events 1 • 12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place